We suspect that our results on GAS5 and miR-222 expression pattern in younger AML patients would be more clearly defined in their effects on clinical parameters, if the analysis were to be performed in patients who were extensively characterized on a molecular level (i.e., using targeted NGS for most common leukemia-associated mutations), as well as if the impact of other significant variables was grouped in a multivariate approach. Here, GAS5 is linked to acute myeloid leukemia.